Redeye leaves a comment following the phase IIa topline results of IP2018 announced by the company earlier today. We are encouraged to learn that the candidate expressed statistically significant (dose-dependent) efficacy in patients with mild to moderate psychogenic ED. Accordingly, we raise our base case valuation of Initiator Pharma.